Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AIDS Therapies
Continued Development of Coactinon Announced
September 3rd, 2000
Triangle Pharmaceuticals, Inc. (VIRS), Durham, North Carolina, announced its continued development of Coactinon in support of an NDA [New Drug Application] filing. Coactinon is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection. This action follows notification from the U.S. Food and Drug Administration (FDA) in December 1999 that additional Phase III studies would be required. Study MKC-401 was ongoing at the time. "After careful analysis and consideration of the potential benefits Coactinon may provide HIV infected patients, we have decided to move forward with its clinical development and remain committed...
Source: Medical Letter on the CDC & FDA (2000-09-03)
|
